Spyre Therapeutics
SYRE
SYRE
84 hedge funds and large institutions have $328M invested in Spyre Therapeutics in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 32 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
84
Holders Change
-8
Holders Change %
-8.7%
% of All Funds
1.48%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
3
Increased
23
Reduced
32
Closed
11
Calls
$340K
Puts
$119K
Net Calls
+$221K
Net Calls Change
+$770K
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$5.56M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$4.82M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.98M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.76M |
| 5 |
SCM
Sio Capital Management
New York
|
+$1.68M |
